Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18161622 | 0.82 | CYP2C9 (0.38) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL11477981 | 0.81 | CPA1 (0.35) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL10495 | 0.79 | CYP2C9 (0.37) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL12015008 | 0.78 | HRH4 (0.36) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL1402037 | 0.78 | CYP2C9 (0.58) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL6132965 | 0.76 | CYP2C9 (0.60) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL1908703 | 0.75 | HRH3 (0.41) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL6124221 | 0.75 | CPA1 (0.33) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL6368933 | 0.74 | CYP2C9 (0.33) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL12226755 | 0.73 | CPA1 (0.33) | CYP2C9TSHRCYP2C19MTORHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | LYPLAL1, PLA2G12A, ENPP2 | CYP2C9 2467/4885TSHR 2563/4885CYP2C19 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.